ATGC-OP0359

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameATGC-OP0359

Drug Alias Nameprostate cancer immunotherapeutic (Avanti Therapeutics)Herpes simplex thymidine kinase (AV-tk)-encoding adenoviral vector + antiherpetic prodrug (Avanti)ATGC-OP0359

ClassificationBiologics

Mechanisms of ActionThymidine kinase stimulants

TargetsThymidine kinase

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryWorld

CombinationsYes

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAvanti Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAvanti Biosciences Inc

Active IndicationsN/A

Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A